The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Top Cited Papers
Open Access
- 9 February 2009
- journal article
- review article
- Published by Springer Nature in Nature Reviews Microbiology
- Vol. 7 (3) , 226-236
- https://doi.org/10.1038/nrmicro2090
Abstract
This Review provides an overview on the spike (S) protein of severe acute respiratory syndrome-coronavirus (SARS-CoV) as a target for the development of vaccines and therapeutics for the prevention and treatment of SARS. SARS is a newly emerging infectious disease, caused by SARS-CoV, a novel coronavirus that caused a global outbreak of SARS. SARS-CoV S protein mediates binding of the virus with its receptor angiotensin-converting enzyme 2 and promotes the fusion between the viral and host cell membranes and virus entry into the host cell. SARS-CoV S protein induces humoral and cellular immune responses against SARS-CoV. SARS S protein is the target of new SARS vaccines. These vaccines are based on SARS-CoV full-length S protein and its receptor-binding domain, including DNA-, viral vector- and subunit-based vaccines Peptides, antibodies, organic compounds and short interfering RNAs are additional anti-SARS-CoV therapeutics that target the S protein. The work on SARS-CoV S protein-based vaccines and drugs will be useful as a model for the development of prophylactic strategies and therapies against other viruses with class I fusion proteins that can cause emerging infectious diseases.Keywords
This publication has 144 references indexed in Scilit:
- Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infectionVaccine, 2008
- Clathrin-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus into Target Cells Expressing ACE2 with the Cytoplasmic Tail DeletedJournal of Virology, 2007
- Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivityBiochemical and Biophysical Research Communications, 2007
- Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodiesProceedings of the National Academy of Sciences, 2007
- Synthetic Reconstruction of Zoonotic and Early Human Severe Acute Respiratory Syndrome Coronavirus Isolates That Produce Fatal Disease in Aged MiceJournal of Virology, 2007
- SARS coronavirus and innate immunityVirus Research, 2007
- Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for Severe Acute Respiratory Syndrome coronavirus (SARS-CoV)Vaccine, 2006
- An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirusNature Medicine, 2004
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994